All In Biotech

Drug Trial Radar · NCT03995108

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31

Actual

Start

Oct 24, 2019

Primary completion

Dec 23, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.

Conditions

  • WHIM Syndrome

Interventions

  • MavorixaforDrug

    Mavorixafor provided as 100 mg capsules.

  • PlaceboDrug

    Placebo matching to mavorixafor capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Placebo-Controlled Period: Time (in Hours) Above Threshold-Absolute Neutrophil Count (TAT-ANC in hours) of ≥ 500 Cells/Microliter (µL) over a 24-hour periodTime frame: Time 0 (pre-dose, up to 15 minutes prior), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ± 15 min) post-dose at Baseline, Weeks 13, 26, 39, and 52
  2. Open-Label Period: Percentage of Participants With Adverse Events (AEs)Time frame: From Day 1 (end of randomized period) up to end of study (30 days post-treatment in open-label period [Week 56 of open-label period])

Locations

23 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California San Diego Health/Rady Children's Hospital

    San Diego, California

  • California Dermatology Institute

    Thousand Oaks, California

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins University Medical Center

    Baltimore, Maryland

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Wesley Hospital

    Auchenflower, Queensland, Australia

  • Children's Health Queensland Hospital

    South Brisbane, Queensland, Australia

  • Medical University of Vienna - Medizinische Universität Wien

    Vienna, Austria

  • Aarhus University Hospital

    Aarhus, Denmark

  • CHU Paris Est, Hôpital d'Enfants Armand-Trousseau

    Paris, France

  • Hopital Necker-Enfants Malades

    Paris, France

  • CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique

    Lyon, Rhne, France

  • University of Debrecen, Affiliated Department of Infectology

    Debrecen, Hajdú-Bihar, Hungary

  • HaEmek Medical Center

    Afula, Israel

  • Università degli Studi di Brescia, Scienze Cliniche e Sperimentali

    Brescia, Piazza Del Mercato, Italy

  • Emma Children's Hospital Academic Medical Center (AMC)

    Amsterdam, Netherlands

  • Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

    Moscow, Russia

  • Academician I.P. Pavlov First Saint Petersburg State Medical University

    Saint Pertersburg, Russia

  • Seoul National University Hospital, Children's Hospital

    Seoul, South Korea

  • Hospital Sant Joan de Deu Barcelona

    Barcelona, Esplugues de Llobregat, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Sevilla, Spain

  • Cukurova University Faculty of Medicine

    Sarıçam, Adana, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.